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Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer characterized by multiple molecular
alterations, the presence of an intense stroma, poor perfusion, and resistance to therapy. In
addition to standard imaging techniques, experimental imaging strategies, such as those utilizing
molecular probes, nanoparticle-based agents, and tagged antibodies are actively being explored
experimentally. It is hoped that advances in these technologies will allow for detecting PDAC at
an early stage, and could serve to validate experimental therapies, rapidly identify non-responders,
and assist in the design of novel therapeutic strategies tailored to the patient’s molecular profile.
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1. PDAC: an overview
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related
death in United States with an overall 5-year survival of 5% [1]. Despite remarkable
advances in the past two decades that have greatly improved our understanding of the
pathobiology of PDAC, overall median survival in PDAC is a dismal 8 to 12 months in
patients with localized disease, and 4 to 6 months in patients with metastatic disease [2].
These alarming statistics are due to multiple factors, including the paucity of specific
symptoms even when PDAC is already well-established, the absence of specific and
sensitive markers that would allow for early stage diagnosis, and the advanced stage at
presentation which precludes resection. Moreover, there is a high recurrence rate following
resection, and most therapeutic approaches are of limited effectiveness due to intrinsic
chemoresistance and radioresistance of the cancer cells, and the presence of a dense stroma
rich in collagens and mucins that combine to prevent therapeutic agents from penetrating the
tumor mass. Together, these alterations exacerbate response to therapy [3, 4], and even new
combinatorial treatment regimens only prolong survival for a few months [5].
© 2013 Elsevier Ireland Ltd. All rights reserved.
*Corresponding author: Murray Korc, MD, School of Medicine, Indiana University, Walther Hall R3 C528, 980 West Walnut Street,
Indianapolis, IN 46202, USA, mkorc@iu.edu.†Current address: The Institute of Cancer Research, Division of Radiotherapy and Imaging, 15 Cotswold Road, Sutton, Surrey, SM2
5NG, United Kingdom
Conflicts of interest
None declared
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Cancer Lett. Author manuscript; available in PMC 2014 December 01.
Published in final edited form as:
Cancer Lett. 2013 December 1; 341(2): 132–138. doi:10.1016/j.canlet.2013.08.008.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
This review will focus on the potential role of imaging modalities such as computed
tomography (CT), magnetic resonance imaging (MRI), ultrasonography (US), positron
emission tomography (PET), and optical imaging that could be combined with molecular
profiling to assist in the identification of novel biomarkers to improve diagnosis, predict
therapeutic responses, and identify new molecular targets, thereby potentially pointing to
strategies that will improve the management and survival of PDAC patients.
2. Molecular Pathogenesis of PDAC
PDAC is believed to arise from precursor lesions that develop into invasive carcinoma
through a multistep carcinogenic process. The most common pre-neoplastic lesion that has
been found in approximately 80% of patients with PDAC is pancreatic intraepithelial
neoplasia (PanIN) [6]. PanIN lesions are classified as PanIN1A, PanIN1B, PanIN2 and
PanIN3, depending on the grade of architectural and nuclear atypia. Thus, PanIN1A lesions
consist of columnar cells forming ductal-like structures and exhibit an abundance of mucin
which stains intensely with Alcian blue (Fig. 1A). PanIN1A lesions are also seen in patients
with chronic pancreatitis and in the elderly, but they are not necessarily pre-malignant [7].
Similarly, PanIN1B lesions are not necessarily pre-malignant and are distinguished from
PanIN1A by the presence of papillary structures (Fig. 1B, C). PanIN progression is
associated with increasing cellular and nuclear atypia, a cribriform appearance, varying
degrees of loss of polarity, and luminal budding. PanIN3 lesions represent a carcinoma in
situ, and may harbor mitotic figures and exhibit local invasion.
PanIN may arise in regions of acinar-to-ductal metaplasia (ADM), and it has been suggested
that progenitor cells giving rise to the acinar cell lineage give rise to ADM and PanIN
lesions, and ultimately PDAC [8, 9]. Other precursor lesions include intraductal papillary
mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN), which harbor specific
molecular alterations [10].
PDAC is characterized by a high frequency of major driver mutations, including KRAS
(95%), CDKN2A (90% mutated, 10% epigenetically silenced), TP53 (70%), and SMAD4
(55%), as well as by low-frequency driver mutations that yield a unique tapestry of gene
alterations in any individual with PDAC [11, 12].
PDAC is also characterized by constitutive activation of pro-survival pathways including
STAT3, NFkB, and AKT, which serve to enhance apoptosis resistance. In addition, there is
excessive production of receptor tyrosine kinases (RTKs) and ligands. For example, the
EGF receptor (EGFR) is a pivotal RTK that is overexpressed at both the mRNA and protein
level in 50-60% of resectable PDACs [13], whereas the human EGF receptor 2 (HER2) is
overexpressed in 45-70% of PDAC cases [14], and this overexpression may be associated
with more aggressive disease and poor clinical outcome [15]. Furthermore, HER3, which
has the capacity to excessively activate PI3K/AKT due to phosphorylation of its 7 tyrosine
residues upon receptor heterodimerization, is overexpressed in 60% of resectable PDAC,
and this overexpression correlates with decreased survival irrespective of ligand levels [16].
Recent studies indicate that pancreatic-cancer cells carry an average of 63 genetic alterations
per cancer, which can be grouped to 12 core signaling pathways [12]. In addition, PDAC is
associated with increased cyclin D1 expression, aberrant activation of transforming growth
factor-beta (TGF- ) pathways in conjunction with increased expression of TGF- isoforms,
and a hypoxic microenvironment rich in inflammatory cells and cytokines that promote
cancer growth [7]. In addition, there is inappropriate reactivation of developmental
pathways, such as Hedgehog (Hh), notch and wnt/ -catenin whose roles have been
comprehensively summarized [6, 17, 18]. Taken together, these observations underscore the
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complexity of the genetic and molecular mechanisms that drive PDAC aggressiveness and
the need for a personalized approach in PDAC treatment. Moreover, they point to novel
candidates for drug and imaging agent targeting. Such an approach has been shown to be
successful using trastuzumab and affibody molecules in HER2-overexpressing breast cancer
cells [19-21].
3. PDAC Microenvironment
PDAC is a highly desmoplastic cancer. The prominent stroma is a complex structure that
consists of proliferating pancreatic stellate cells (PSC), cancer-associated fibroblasts,
degenerating acinar cells, foci of aberrant micro-angiogenesis, and varying types of
inflammatory cells [22]. The stromal compartment plays an active role in promoting
invasion and growth of PDAC cells, and at the same time, is a physical barrier for drug
delivery [23]. PSCs have a strategic role in stroma formation, and are involved in tumor
growth, invasion and metastasis [24, 25]. Upon activation, they synthesize and release
growth factors and produce large amounts of extracellular matrix (ECM) proteins leading to
ECM remodeling, and finally, to a hypovascular and hypoxic stroma [10].
The role of angiogenesis in PDAC remains controversial. Early data correlating microvessel
hot spots in PDAC with known modulators of angiogenesis, as well as analysis of
angiogenesis in orthotopic mouse models of PDAC, have suggested that PDAC is
angiogenesis-dependent, but angiogenesis inhibitors have failed in clinical trials [26-28].
With the establishment of genetically engineered mouse models (GEMs) of PDAC, it
became possible to gain a better understanding of the role of key genes and pathways
involved in PDAC initiation and progression, identify new predictive biomarkers, validate
novel therapeutic approaches, and evaluate the mechanisms responsible for chemoresistance.
A number of murine PDAC (mPDAC) models have been generated by targeting a
conditionally mutated Kras allele (LSL-KrasG12D) to pancreatic progenitors, using Cre
recombinase driven by either Pdx1 or Ptf1a promoters [42]. This so-called KC (KrasG12D
allele and Cre-driven recombinase) GEM is characterized by slow PanIN progression to
invasive mPDAC and a low incidence of metastasis (average latency 1 yr) [29, 30]. By
contrast, combining oncogenic Kras with inactivation of tumor suppressor genes, such as
Ink4a, p53 and SMAD4 markedly accelerated PanIN progression to mPDAC [30-32].
Moreover, the dense stroma that occurs in these GEMs exhibits features that resemble
human disease. For example, mPDAC arising in Pdx1-Cre/KrasG12D/p53R172H mice, which
harbor heterozygous conditional mutant alleles of KRAS and p53, exhibit marked
hypovascularity and aberrant vascular architecture [33]. The dense stroma and the
hypovascularity are important contributors to chemoresistance, and targeting the stromal
hedgehog pathway attenuates desmoplasia and improves tumor vascularization leading to
increased drug delivery [23]. However, in an oncogenic Kras-driven GEM that lacks
p16Ink4a and glypican-1 (GPC1), mPDACs display attenuated angiogenesis and growth [34].
This is due to loss of the pro-angiogenic actions of heparin-binding growth factors that
depend on the presence of GPC1 [34]. Thus, in spite of the paucity of blood vessels in this
mPDAC model and its marked desmoplasia, tumor angiogenesis can nonetheless contribute
to mPDAC biological aggressiveness.
4. The Need for Imaging Advances in PDAC
Molecular imaging plays an important role in cancer management and has been successfully
employed for tumor detection and characterization, staging, and response to therapeutic
intervention. The primary advantage of in vivo imaging is the ability to characterize
malignancies in a non-invasive way, and at the same time, provide quantitative data.
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The use of imaging in clinical practice in PDAC has proven challenging due to the
retroperitoneal location of the pancreas. Currently, the most common modalities that have
been used to image the pancreas include CT, MRI and endoscopic ultrasonography (EUS),
but these methods are limited to diagnosis and staging. Recently, however, radionuclide
imaging using PET and 18F-FDG has shown promise. Moreover, optical technologies such
as near infrared imaging and multispectral optoacoustic imaging that are mainly used
experimentally, may be translated into the clinic in the near future.
Each of these imaging modalities have variable sensitivities, and enable visualization of
malignant tissues from different perspectives, such as tissue density, metabolism, vascularity
and/or water content (Table 1). While conventional radiological techniques improve the
specificity of PDAC diagnosis, they are limited by their ability to detect PDAC at a
resectable stage that precedes perineural invasion, vascular involvement and the formation
of distant metastases. Therefore, there is a dire need to improve their sensitivity, specificity
and accuracy to improve early stage diagnostics and identify specific biomarkers and
molecular probes.
The development of preclinical models that recapitulate the human disease in vivo has aided
in the identification of novel biomarkers, and the development of screening strategies to
improve clinical outcome. Among the various biomarker candidates and diagnostic tools
identified and studied thus far standouts include integrin ligands, plectin-1, cathepsin
activity, nanoparticle-based agents, antibodies and contrast agents, all of which have shown
promising results in experimental settings. These probes used in conjunction with molecular
imaging techniques could serve as the guides for i) detection of early cancer, ii) validation of
putative drugs and different treatment regimens, and iii) early identification of non-
responders. Such approaches would lead to patient stratification through a precise
personalized approach for targeting patient-specific pathway alterations in the tumor. Next,
we highlight new advances in PDAC imaging, the advantages and disadvantages of different
modalities used to detect primary and metastatic lesions, and describe their potential
usefulness as predictive tools for targeted therapy.
5. Imaging modalities
Endoscopic ultrasound (EUS) involves the use of a high-frequency ultrasound (US)
transducer that was developed in the early 1980s specifically to better visualize the pancreas
[35]. US relies on the reception, analysis and display of acoustic signals produced by
reflection or backscatter of sound above the audible frequency range for humans (>20 kHz).
In contrast to other imaging modalities, it offers significant advantages such as real-time
imaging acquisition, wide availability, safety and low cost. This technique, however, is
limited by operator dependence, resulting in variable accuracy ranging from 57% to 81%
[36]. Introduction of Doppler-based methods for assessing the direction and velocity of
blood flow have expanded the diagnostic capabilities of US, but Doppler cannot be used to
assess microvascular blood flow of tissues.
EUS can provide reliable information about the size and local extent of the primary tumor.
By guiding the probe in close proximity to the pancreas, clinicians can image the whole
organ, and biopsy suspicious masses under direct visualization thereby obtaining detailed,
high resolution images and tissue samples for pathological evaluation. The development of
electronic radial and linear transducers as well as color Doppler capabilities has also
improved the accuracy of diagnosis and staging, establishing EUS as the procedure of
choice for the evaluation of patients with pancreatic cancer [37]. Currently, the sensitivity of
EUS for detecting pancreatic lesions ranges from 85% to 99%, which is higher than the
sensitivity of CT in detecting small pancreatic nodules [38]. Furthermore, the method is able
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to detect focal lesions as small as 2-3 mm and can be as accurate as CT in detecting liver
metastases [39]. The bulk of the literature supports its superiority over CT, MRI and PET for
pancreatic tumor detection and local staging [40, 41]. However, in order to predict tumor
resectability, the combination of CT and EUS proved to be the most accurate method
compared to either modality alone [42]. Moreover, EUS-guided Fine Needle Aspiration
(EUS-FNA) allows for tissue sampling and cytological evaluation of the primary tumor and
adjacent suspicious lymph nodes that are difficult to detect by CT or MRI. This procedure
has had a major impact on therapeutic management of the patients by providing a definite
tissue diagnosis, with an overall 85%-90% sensitivity and almost 100% specificity [43, 44].
The advent of contrast medium agents has enhanced the ability to obtain essential
quantitative information relating to tissue vascularity, perfusion and even endothelial wall
function. The most commonly used contrast agents are gas-filled microbubbles. Their purely
vascular localization makes them ideal for the development of targeted contrast agents,
especially in relation to receptors expressed on the endothelial lining of vessels. Currently,
contrast-enhanced US imaging is only used in pre-clinical studies. For example,
microbubble-enhanced US was recently used as a method to noninvasively monitor the
functional effects of an anti-angiogenic agent in GEMs of PDAC [45]. However, ongoing
research indicates it might be soon translated into clinical trials.
CT imaging is based on the measurements of the attenuation of x-rays passing through an
object and provides excellent anatomic context. It also supports separately acquired
emission images of the distribution of radiolabeled agents, and increases their accuracy by
providing attenuation correction of the emission intensities. Currently, it is widely used for
initial diagnosis and staging of pancreatic cancer and liver metastases [46]. Introduction of
dual-phased multi-detector CT (MDCT), which uses a wider x-ray beam, narrower detector
collimation, and more rapid table translation, resulted in much faster image acquisition
during different temporal phases compared with conventional CT [47]. Additionally, it has
allowed for imaging of larger volumes of pancreatic tissue while providing useful
information on arterial and venous phases, and better delineation of the main pancreatic duct
and small intra-parenchymal masses. Moreover, introduction of more sophisticated
reconstruction algorithms have resulted in better contrast and spatial resolution images that
together have improved detection and staging of PDAC.
To date MDCT has the highest accuracy in assessing the extent of the primary tumor, loco-
regional extension, vascular invasion, distant metastasis, tumor-node-metastasis (TNM)
stage and tumor resectability. MDCT has been used in the preoperative staging of PDAC,
with a sensitivity and specificity for predicting resectability of 96% and 33%, respectively
[48]. Despite its sensitivity for detecting potentially respectable tumors, MDCT is rather
nonspecific, therefore, detection of cystic lesions or lesions <2 cm might be challenging by
this technique [49]. Moreover, this technique cannot reliably differentiate between benign
and malignant lesions. Thus, other modalities with higher specificity should be considered
for PDAC staging. Recently, perfusion CT, which quantifies tissue perfusion following
contrast agent administration, has shown promise in detecting pancreatic tumors with higher
specificity, and differentiating low-grade from high-grade PDAC [50, 51]. However, the
accuracy of this method depends on hypovascular PDACs that exhibit diminished levels of
contrast enhancement compared to the surrounding pancreas.
PET imaging is based on the decay of a radioisotope, which emits a positron from the
nucleus that subsequently annihilates with an electron to produce two high-energy (511
keV) photons that propagate in nearly opposite directions. The information provided by this
modality, including tissue function, blood flow, metabolic activity and receptor expression,
is useful for diagnosis, staging, treatment and management of cancer. PET is particularly
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helpful in the evaluation of distant metastases, and in instances of an equivocal CT or MRI
diagnosis. Moreover, unlike anatomical imaging modalities that measure changes in tumor
volume, PET allows treatment effects to be directly monitored at earlier time points before
any tumor volumetric changes are visible on standard CT or MR images.
The tracer that has had a major impact on clinical PET imaging, and is considered a gold
standard is 18F-fluorodeoxyglucose (18F-FDG). It is an analog of glucose taken up by the
cancer cells through the glucose transport pathway, but it cannot be metabolized and
therefore remains trapped within metabolically active tissues. The normal pancreas has low
glucose utilization compared with tumors. Therefore, foci of abnormal 18F-FDG uptake can
be easily visualized as focal areas of increased activity (Fig. 2). Gambhir et al., in their
tabulated review, demonstrated that in 387 PDAC patients, the average sensitivity and
specificity of 18F-FDG were 94% and 90%, respectively, compared to 82% and 75% for CT
[52]. Similar results were obtained by Keogan et al., who reported that this non-tumor-
specific molecule has high sensitivity (88-92%) and specificity (83%-85%) for diagnosing
primary PDAC [53].
The presence of focal 18F-FDG activity also provides a significant advantage for diagnosing
small metastatic lesions. However, since glucose metabolism is not specific for malignant
processes, physiologic 18F-FDG uptake can be found in normal tissues (brain, muscles,
salivary gland, myocardium, urinary tract) as well as in inflammatory and benign lesions,
which might lead to false positive or false-negative findings. As a result, chronic pancreatitis
and PDAC may have a similar appearance [54]. Fendrich et al., showed strong 18F-FDG
uptake in mPDAC, but a weak signal in the pancreata of mice with PanIN lesions,
suggesting that glucose metabolism increases during PDAC progression [55]. These findings
undoubtedly support further exploration of PET imaging and support the statement that, in
general, it is the combination of PET with CT and/or MRI that improves the sensitivity for
diagnosing a malignancy compared with each modality alone.
The role of 18F-FDG is staging, however, is questionable. Poor spatial resolution limits the
local staging of PDAC, and primary tumors should be evaluated by modalities that image
the tumor relative to adjacent organs and vascular structures, such as EUS, CT, MRI. On the
other hand, PET is useful for identifying distant metastases [56]. Thus, the sensitivity and
specificity of 18F-FGD-PET for detecting hepatic metastases was 95%, only missing liver
lesions <1 cm [57]. The impact of 18F-FDG on patient management is not clearly evident.
There are no accepted screening tests that would identify early stage PDAC and there is no
justification for using 18F-FDG as a population screening tool. Moreover, by the time
patients undergo any form of imaging, there is an 80% chance that the disease is at an
advanced stage and has become unresectable. Therefore, there is a dire need to develop
imaging platforms with enhanced abilities to visualize specific molecular markers at the
initial stages of PDAC development.
MRI techniques involve manipulation of nuclear magnetic dipole moments by means of
externally applied magnetic fields, and the subsequent recording and mathematical analysis
of radio signals emitted from the nuclei in response to these manipulations. This imaging
modality can provide information about tissue structure, perfusion and function (Magnetic
Resonance Spectroscopy). One of the key advantages of MRI over CT is superior contrast
among soft tissues. Moreover, MRI has multiplanar capabilities that are absent from CT.
The sensitivity of MRI is low but can be improved by introducing contrast agents that
magnetically modify the environment affecting either T1 or T2 relaxation time constants,
proton density, or nuclear polarization. By contrast, the spatial resolution of MRI is
extremely good ( m), and is not limited by excitation wavelength or the diffraction limit of
photons. Some consider MRI to be the best first line noninvasive imaging modality in
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suspected PDAC patients, since it can evaluate pancreas (benign vs. malignant), vasculature
and pancreaticobiliary ducts in a single examination [37]. Due to its high soft tissue contrast
and more extensive types of data that can be acquired, some argue that MRI is even more
predictable than CT in evaluation of pancreatic tumors, especially in detecting small non-
contour-deforming lesions and subtle liver metastasis [58].
Diffusion-weighed imaging (DWI) is a relatively new MRI technique that reflects changes
in water mobility caused by interactions with cell membranes and macromolecules, and
alterations in the tissue environment. Therefore, DWI provides a tissue contrast that is
different from that of conventional T1- and T2-weighted MRI images. Inasmuch as DWI
offers quantitative measurements of the diffusivity of water described by the apparent
diffusion coefficient (ADC), it represents microcirculation of blood perfusion and the
molecular diffusion of water. Therefore, in pancreatic cancer, ADC values are usually lower
than in normal pancreatic tissue. Using DWI, Kamisawa et al., evaluated its clinical utility
in patients with cancer and autoimmune pancreatitis (AIP), and assessed whether DWI could
help differentiate cancer from AIP [59]. They determined that ADC values were
significantly lower in AIP than in PDAC and normal pancreas, underscoring the potential of
DWI as a diagnostic test in AIP.
Optical imaging is a very sensitive and versatile modality that is based on detecting the
transmission of light through biological tissues. Photons traveling through the tissue
simultaneously undergo absorption, attenuation and scattering that are wavelength and
penetration-depth dependent. Consequently, it is not possible to conduct rigorous
quantitative assessments with this technique. Currently, there are several optical imaging
technologies, such as bioluminescence imaging (BLI), fluorescence imaging (FLI), diffuse
optical tomography (DOT), and optical projection tomography (OPT). All of these imaging
modalities are emerging as powerful tools for measuring dynamic metabolic processes and
probing protease, protein and enzymatic activity in vivo.
In DOT, diffuse light penetrates tissues at multiple projections yielding tomographic images.
Introduction of this technique was a milestone in optical technology, since DOT provides
quantitative information about light absorption, scattering and uptake of fluorescence
contrast agents. OPT technology was developed more recently for 3D imaging, and has
emerged as a powerful tool for visualization of specimen areas with sizes between 1–10 mm.
It is essentially, the optical equivalent of X-ray tomography that is based on the acquisition
of a sequence of optical transmission images through the sample, which is rotated at several
angles. The application of optical imaging to date has been largely investigated in vivo in
murine models providing unique insights into disease pathogenesis, drug development and
the effects of therapy. In this way, optical imaging already is making a substantial impact on
basic and translational medical research.
6. Imaging Experimental Models
BLI holds great potential for experimental research purposes primarily as a high throughput,
small animal imaging modality. It is based on the self-emission of light from yellow to green
wavelengths owing to catalysis of luciferase enzymes that takes place in the presence of
luciferin substrates [60]. The advantage of BLI is the minimal background signal and an
excellent signal-to-noise ratio (SNR), which makes this technique highly sensitive (Fig. 3).
However, due to the fact that it is a two-dimensional planar modality, BLI does not allow for
absolute quantification of target signal. FLI refers to the property of certain molecules to
absorb light at a particular wavelength and to emit light of a longer wavelength after a brief
interval known as the fluorescence lifetime [61]. Both, BLI and FLI modalities using
specific promoters to drive reporter gene expression provides the ability to localize and
Kramer-Marek et al. Page 7
Cancer Lett. Author manuscript; available in PMC 2014 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
measure gene and protein expression, and monitor cell trafficking, tumor growth and
responsiveness to new therapies.
In orthotopic pancreatic cancer models, Bouvet et al., used BxPC-3 and MiaPaCa-2
pancreatic cancer cell lines that stably and robustly express GFP to demonstrate external,
real-time, whole body and intravital fluorescence imaging of tumor growth and metastasis
progression [62]. Also, the near-infrared fluorescently-labeled recombinant protein, PTD-
ODD-HaloTag (POH), allowed for the successful monitoring of HIF-active regions within
small localized and metastatic foci in an orthotopic pancreatic mouse model, in which HIF
positive cancer cells play a central role during local invasion and metastasis [63].
Fluorescent images combined with BLI identified HIF(+) cancer cells at 9–24 h after
intraperitoneal injection of labeled agent [63]. Moreover, in a PDAC GEM, it was recently
demonstrated that a cathepsin-activated NIRF probe can be used with the vascular contrast
agent fluorescein to differentiate between low-grade and high-grade murine PanINs and
early-stage mPDAC in vivo, combining the advantages of IHC and real-time confocal
fluorescence laser microscopy in a KrasG12D-driven mouse model [64].
7. Conclusions
Current demands and trends call for new strategies to focus on the discovery of novel
biomarkers specific for PDAC that distinguish between different stages and grades of PDAC
and perhaps allow for earlier disease detection. Such biomarkers could also serve as
prognostic tools or as potential therapeutic drug targets. Improved imaging and screening
protocols could allow for the screening of high risk populations, patient-specific treatment
selection, and imaging-based therapy monitoring. Taken together, these strategies could
ultimately improve therapeutic options in this deadly cancer.
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Fig.1.
PanIN Lesions. (A) PanIN-1 lesions accumulate mucins, evidenced by Alcian blue staining.
(B) H&E stain of human pancreas showing PanIN-1A (arrows) and PanIN-1B (arrowhead)
lesions adjacent to a PanIN-2 (boxed). (C) High magnification image of the PanIN-2 lesion
in (B) showing luminal budding, and nuclear elongation and loss of polarity.
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Fig.2.
Axial PET (A), CT (B), and fused PET/CT (C) images of a 78 year-old female with a
hypermetabolic mass (SUVmax 3.9) in the tail of the pancreas. The image is compatible
with primary PDAC (arrows). Figure courtesy of Dr. Gregory Ravizzini from MD Anderson
Cancer Center.
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Fig.3.
BLI of pancreatic T3M4-Luc tumors in a mouse orthotopic model. Mice were injected with
1.5×105 T3M4-Luc cells and imaged 21 days later. Regions of interest (ROI) show
integrated light signal in both tumors scaled to the maximum value and measured in
photons/second (Ph/s).
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Table 1
A summary of the most commonly used imaging modalities.
Imaging Modality Resolution Sensitivity[Moles/l] Imaging Agents Cost
Clinical/
Animal Use
PET
1-2 mm
(microPET);
4-5 mm (clinical
PET)
~10−11-10−
12
FDG, FLT, choline,
acetate,
nitroimidazole,
antibody and
antibody fragments
High Yes/Yes
CT 15-200 m ~10−4 IodineBarium High
Yes/bone and
lung imaging
MRI 10-100 m ~10−3-10−5
Gadolinium (+3), iron
oxide particles,
manganese oxide
High Yes/Yes
Ultrasound >40 m a singlebubble Contrast microbubles Low Yes/Yes
Bioluminescence
Fluorescence
several mm
2-3 mm ~10
−15
Fluorescent
molecules and dyes,
targeted
nanoparticles
Low No/Yes
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